.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Harvard Business School
Dow
Baxter
Mallinckrodt
Citi
Covington
Accenture
Queensland Health

Generated: November 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,591,762

« Back to Dashboard

Claims for Patent: 5,591,762

Title: Benzimidazoles useful as angiotensin-11 antagonists
Abstract:Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
Inventor(s): Hauel; Norbert (Schemmerhofen, DE), Narr, deceased; Berthold (late of Biberach, DE), Ries; Uwe (Biberch, DE), van Meel; Jacobus C. A. (Mittelbiberach, DE), Wienen; Wolfgang (Biberach/Rissegg, DE), Entzeroth; Michael (Warthausen, DE)
Assignee: Dr. Karl Thomae GmbH (Biberach an der Riss, DE)
Application Number:08/457,204
Patent Claims: 1. A compound of the formula I ##STR30## wherein R.sub.1 is in the 4-position and represents a C1-4-alkyl, C.sub.3-7 -cycloalkyl or trifluoromethyl group,

R.sub.2 represents a benzimidazol-2-yl group optionally substituted in the 1-position by C.sub.1-6 -alkyl or C.sub.3-7 -cycloalkyl group, whilst the phenyl nucleus of the above-mentioned benzimidazole groups may additionally be substituted by a fluorine atom or by a methyl or trifluoromethyl group,

R.sub.3 represents a C.sub.1-5 -alkyl group or cyclopropyl, and

R.sub.4 denotes a 1H-tetrazolyl group or an R.sub.a O--CO-- group, wherein

R.sub.a denotes a hydrogen atom or a straight-chained or branched C.sub.1-4 -alkyl group,

or a pharmaceutically acceptable salt thereof.

2. In accordance with claim 1, a compound of the formula I, wherein

R.sub.2 is in the 6-position,

or a pharmaceutically acceptable salt thereof.

3. In accordance with claim 2, a compound of the formula I, wherein

R.sub.1 represents a methyl group,

R.sub.2 represents a benzimidazol-2-yl group optionally substituted in the 1-position by a C.sub.1-3 -alkyl group, whilst the phenyl nucleus of one of the above-mentioned benzimidazole groups may additionally be substituted by a fluorine atom,

R.sub.3 represents a C.sub.1-5 -alkyl group, and

R.sub.4 represents a carboxy or 1H-tetrazolyl group,

or a pharmaceutically acceptable salt thereof.

4. A compound selected from the group consisting of:

(a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]- methyl]-biphenyl-2-carboxylic acid,

(b) 4'-[[2-n-propyl-4-methyl-6-(1 -methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)- biphenyl,

(c) 4'-[(2-n-propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimida zol-1-yl)-methyl]-biphenyl-2-carboxylic acid,

(d) 4'-[[2-n-butyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-m ethyl]-2-(1H-tetrazol-5-yl)-biphenyl,

(e) 4'-[[2-n-propyl-4-methyl-6-(1-methyl-6-fluoro-benzimidazol-2-yl)-benzimida zol-1-yl]-methyl]-biphenyl-2-carboxylic acid,

(f) 4'-[(2-ethyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol -1-yl)-methyl]-biphenyl-2-carboxylic acid,

and pharmaceutically acceptable salts thereof.

5. 4'-[[2-n-Propyl-4-methyl-6-(1-methylbenzimi dazole-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

6. 4'-[[2-n-Propyl-4-methyl-6-(1-methylben zimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1, 2, 3, 4, 5, or 6.

8. A method for treating hypertension which comprises administering to a mammalian host suffering from the same an antihypertensive amount of a compound of claims 1, 2, 3, 4, 5 or 6.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Queensland Health
Novartis
Daiichi Sankyo
Fuji
Colorcon
Cipla
Accenture
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot